Phagenesis is a pioneering medical technology company focused on transforming the treatment of dysphagia, a condition that affects the ability to swallow. Operating in the healthcare sector, Phagenesis serves patients suffering from neurogenic dysphagia, often resulting from conditions like stroke. The company’s core product, Phagenyx, is a revolutionary treatment designed to restore swallow function in just 10 minutes per day over a 3-day period for most patients. Phagenesis operates on a business-to-business model, partnering with hospitals and medical institutions to deliver its innovative solutions. Revenue is generated through the sale of its medical devices and associated treatment protocols. The company has received significant recognition, including FDA Breakthrough Device Designation, underscoring its commitment to scientific and clinical excellence.

Keywords: dysphagia, neurogenic, Phagenyx, stroke, swallow function, medical technology, FDA, healthcare, treatment protocols, clinical excellence.